Microenvironmental M1 tumor-associated macrophage polarization influences cancer-related anemia in advanced ovarian cancer: Key role of interleukin-6

Haematologica

Volumn 103, Issue 9, 2018, Pages e388-e391

  Madeddu, Clelia ^a   Gramignano, Giulia ^b   Kotsonis, Paraskevas ^c   Coghe, Ferdinando ^d   Atzeni, Vinicio ^c   Scartozzi, Mario ^a   Macciò, Antonio ^c  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b San Gavino Hospital   (Italy)

^c BROTZU HOSPITAL   (Italy)

^d Azienda Ospedaliera Universitaria Cagliari   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; C REACTIVE PROTEIN; CD14 ANTIGEN; CD163 ANTIGEN; FERRITIN; FIBRINOGEN; HEMOGLOBIN; HEPCIDIN; HLA DR ANTIGEN; IMMUNOGLOBULIN G1; INTERLEUKIN 6; REACTIVE OXYGEN METABOLITE; TOCILIZUMAB; TRANSFERRIN; BIOLOGICAL MARKER;

ADULT; ANEMIA; ASCITES FLUID; CANCER STAGING; CELL CULTURE; CELL CYCLE S PHASE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IRON BLOOD LEVEL; IRON DEFICIENCY; IRON METABOLISM; LAPAROSCOPIC SURGERY; LETTER; MACROPHAGE; MAJOR CLINICAL STUDY; MIDDLE AGED; OVARY CANCER; PHENOTYPE; POLARIZATION; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; AGED; CANCER GRADING; COMPLICATION; IMMUNOLOGY; MACROPHAGE ACTIVATION; MALE; METABOLISM; OVARY TUMOR; PATHOLOGY;

AGED; ANEMIA; BIOMARKERS; FEMALE; HUMANS; INTERLEUKIN-6; MACROPHAGE ACTIVATION; MACROPHAGES; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; OVARIAN NEOPLASMS; PHENOTYPE; TUMOR MICROENVIRONMENT;

EID: 85052873643     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2018.191551     Document Type: Letter

References (15)

1. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011-1023.
2. Macciò A, Madeddu C, Gramignano G, et al. The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study. Haematologica. 2015; 100(1):124-132.
3. Davis SL, Littlewood TJ. The investigation and treatment of secondary anaemia. Blood Rev. 2012;26(2):65-71.
4. Soares MP. Macrophages and iron metabolism. Immunity. 2016; 44(3):492-504.
5. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11(10):889–896.
6. Cairo G, Recalcati S, Mantovani A, Locati M. Iron trafficking and metabolism in macrophages: contribution to the polarized phenotype. Trends Immunol. 2011;32(6):241-247.
7. Murray PJ, Allen JE, Biswas SK, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014;41(1):14-20.
8. Freemerman AJ, Johnson AR, Sacks GN, et al. Metabolic reprogramming of macrophages: glucose transporter 1 (GLUT1)-mediated glucose metabolism drives a proinflammatory phenotype. J Biol Chem. 2014;289(11):7884-7896.
9. Luo Y, Tucker SC, Casadevall A. Fc-and complement-receptor activation stimulates cell cycle progression of macrophage cells from G1 to S. J Immunol. 2005;174(11):7226-7233.
10. Biswas SK, Mantovani A. Orchestration of metabolism by macrophages. Cell Metabolism. 2012;15(4):432-437.
11. Obeng JA, Amoruso A, Camaschella GL, Sola D, Brunelleschi S, Fresu LG. Modulation of human monocyte/macrophage activity by tocilizumab, abatacept and etanercept: an in vitro study. Eur J Pharmacol. 2016;80:33-37.
12. Noguchi-Sasaki M, Sasaki Y, Shimonaka Y, Mori K, Fujimoto-Ouchi K. Treatment with anti-IL-6 receptor antibody prevented increase in serum hepcidin levels and improved anemia in mice inoculated with IL-6-producing lung carcinoma cells. BMC Cancer. 2016;16:270.
13. Macciò A, Madeddu C, Gramignano G, Mulas C, Sanna E, Mantovani G. Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-beta for the treatment of anemia in advanced cancer patients undergoing chemotherapy: open-label, randomized controlled study. Oncologist. 2010;15(8):894-902.
14. Cutone A, Rosa L, Lepanto MS, et al. Lactoferrin efficiently counteracts the inflammation-induced changes of the iron homeostasis system in macrophages. Front Immunol. 2017;8:705.
15. Rochette L, Gudjoncik A, Guenancia C, Zeller M, Cottin Y, Vergely C. The iron-regulatory hormone hepcidin: a possible therapeutic target? Pharmacol Ther. 2015;146:35-52.